Print this page
-
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
NCI/CTEP #10466: A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Protocol: 082203Principal Investigator:
- Ryan Stephenson (Rutgers University)
Applicable Disease Sites: Kidney -
An Open-Label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy.
Protocol: 082005Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE].
Protocol: 081910Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
A Multicenter, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy.
Protocol: 082106Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney
